22 August 2022 - Highly accurate, tissue based, next generation sequencing test approved in China as a companion diagnostic for targeted colon cancer therapies.

Pillar Biosciences today announced that its oncoReveal Dx Colon Cancer Assay has received approval from the China National Medical Products Administration.

Read Pillar Biosciences press release